Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
Clinical trial NCT06443671 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06443671
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2026-06-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.